Short description
Syntimmune develops differentiated drug candidates in a wide range of autoimmune diseases.
Description
Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. It is seeking advancing novel therapies based on its expertise in the biology of the neonatal Fc receptor (FcRn) and its role in the pathogenesis of IgG-mediated autoimmune diseases.
Laurence and Richard Blumberg founded Syntimmune in 2013. Its headquarters is in Boston in Massachusetts.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Boston, Massachusetts, United States, North America
Founded on
January 1, 2013
Exited on
September 26, 2018
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccessforu, No Way, Blurry Noaccess
Sign in for full access
Founders
Laurence Blumberg, Richard Blumberg